By Dave Muoio
The government's new National COVID-19 Preparedness Plan has four major goals: to protect against and treat COVID-19, to prepare for new variants of COVID-19, to prevent economic and educational shutdowns and to drive more vaccination outside of the U.S.
read more
By Kevin Dunleavy
Bristol Myers Squibb will soon take up residence in a new R&D campus in San Diego, California, leasing a 427,000 square foot complex in the University Town Center near La Jolla. The agreement will allow BMS to consolidate its R&D units in the area under one roof.
read more
By Conor Hale
If these devices are carried in a chest pocket near or over the heart, they could accidentally switch off implants such as pacemakers and cardioverter defibrillators that are designed to keep a person’s pulse on track.
read more
By Nick Paul Taylor
There’s more trouble in the respiratory syncytial virus (RSV) race. Days after GlaxoSmithKline stopped its maternal vaccine studies, AstraZeneca and Sanofi have revealed their antibody prospect failed to reduce infant hospitalization in a phase 3 clinical trial.
read more
By Anastassia Gliadkovskaya
Civica plans to make three generic insulins, the price of which will be based on the cost of development, production and distribution.
read more
By Eric Sagonowsky
When OxyContin maker Purdue Pharma and its founding family inked a $4.5 billion opioid settlement back in September, the judge overseeing the case called it a "bitter result." Now, thanks to an appeal and extended talks, the settlement just got a lot bigger.
read more
By Fraiser Kansteiner
The contingent of pharma companies condemning Russia’s invasion of Ukraine—and pledging to help keep the beleaguered nation’s healthcare system afloat—is growing.
read more
By Max Bayer
When Russia began to stack troops along Ukraine's border—up to 190,000 of them—Karuna Therapeutics' partners began to prepare clinical trial participants for the company's schizophrenia treatment in psychiatric hospitals across the country.
read more
By Rebecca Torrence
Chronic care management company DarioHealth signed a $30 million multi-year contract with Sanofi to extend the commercial reach of its digital therapeutics to the pharma giant's health plan clients.
read more
By Fraiser Kansteiner
Pfizer and BioNTech recently emerged from a lawsuit unscathed after Allele Biotechnology and Pharmaceuticals cried patent infringement against a trio of pandemic juggernauts. For Regeneron, however, the legal battle is set to roll on.
read more
By Angus Liu
Scientists at the University of Texas at Austin have refined the Cas9 protein used in the CRISPR gene-editing tool. The new version, dubbed “SuperFi-Cas9,” was thousands of times less likely to perform off-target editing while maintaining the efficiency of on-target editing as the original version.
read more
By Conor Hale
The Paris-based company's computer-assisted diagnostic system aims to help ER physicians as well as orthopedic surgeons and family doctors.
read more
By Kevin Dunleavy
A recent doctors' survey, conducted by RBC Capital Markets, shows a strong market exists for Aduhelm or similar beta-amyloid antibodies. If restrictions are loosened or if Biogen gets a positive readout in a phase 3 trial, the analysts see the potential for $8 billion in peak sales from the company's Alzheimer's franchise. The report comes amid another appeal from Congress to reconsider limiting use of the drug to clinical trials.
read more
